Tirzepatide-induced weight loss and obstructive sleep apnea improvement in an adult with type 2 diabetes: A case report.
Medicine (Baltimore) · 2025
Last updated 2026-05-28A 48-year-old man with type 2 diabetes and severe obstructive sleep apnea (OSA) lost weight after starting tirzepatide, dropping from 129 kg to 108 kg in 3 months and eventually to 82 kg. His blood sugar control improved, and his OSA symptoms decreased, allowing supervised withdrawal from CPAP therapy. No severe side effects were reported during the treatment.
AI summary of the abstract below.
| Journal | Medicine (Baltimore), 2025 |
|---|---|
| Citations | 1 |
| Molecules | tirzepatide |
| Conditions studied | Type 2 Diabetes, Obesity, Obstructive Sleep Apnea |
Abstract
RATIONALE: Managing type 2 diabetes mellitus (T2DM) in adults with severe obesity frequently coexists with obstructive sleep apnea (OSA), complicating metabolic control and quality of life. Real-world, objective monitoring-documented trajectories through which pharmacologic weight loss enables withdrawal of continuous positive airway pressure (CPAP) remain clinically informative.
PATIENT CONCERNS: A 48-year-old man (height 178 cm; weight 129 kg; BMI 40.7 kg/m²) had T2DM and severe OSA diagnosed by polysomnography (PSG), with persistent daytime sleepiness despite CPAP and body-weight fluctuations between 108 and 129 kg.
DIAGNOSES: T2DM with class III obesity and severe OSA with prior peak HbA1c of 8.2%.
INTERVENTIONS: Beginning in June 2023, tirzepatide was initiated with gradual dose escalation alongside nutritional counseling and light-to-moderate physical activity. At initiation, it was prescribed for glycemic control and weight reduction in T2DM and thus predated the subsequent U.S. FDA approval for OSA. OSA outcomes were later assessed with objective monitoring via CPAP telemonitoring as part of routine comorbidity care. CPAP was continued initially and reassessed after weight loss.
OUTCOMES: Within 3 months, weight decreased to 108 kg (BMI 34.1 kg/m²) with improved glycemic control. On CPAP telemonitoring, the device-derived residual apnea-hypopnea index decreased and remained low over time. Given sustained weight loss and improved symptoms, CPAP was discontinued under supervision. At the most recent follow-up, the patient weighed 82 kg (BMI 25.9 kg/m²) and reported improved daytime functioning. No severe adverse events occurred.
LESSONS: In selected adults with T2DM and OSA, tirzepatide-associated weight loss may contribute to device-monitored control of OSA on CPAP, enabling supervised withdrawal in carefully selected cases. While single-patient observations cannot establish causality, they complement emerging evidence and can guide patient counseling and hypothesis generation for prospective studies.
Verbatim abstract via PubMed 41137356 ↗
Related research
- Tirzepatide Once Weekly for the Treatment of Obesity.
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
- Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial.
- Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis.
- Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity.
- Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial.
- Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.
- Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial.